FDA’s food-effect guidance signals a narrower, updated path for oral-drug development studies

What changed

FDA posted a guidance document, Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations, providing recommendations for sponsors that plan to conduct food-effect studies for orally administered drug products under INDs to support NDAs and supplements. The policy signal is not simply that FDA updated an old document. The new guidance expressly revises and replaces part of the agency’s 2002 guidance on food-effect bioavailability and fed bioequivalence studies. That matters for development teams still using the 2002 framework as a default reference for food-effect study planning.

Why it matters

Food-effect studies can influence how sponsors design clinical pharmacology programs for oral drug products. FDA’s update indicates that, for IND-to-NDA development and NDA supplements, sponsors should align planned food-effect work with the newer clinical pharmacology recommendations rather than relying only on the superseded portion of the 2002 guidance. The guidance is especially relevant to:

• Regulatory affairs teams managing IND programs intended to support NDAs or supplements.
• Clinical pharmacology groups designing food-effect studies for orally administered drug products.
• Development teams maintaining legacy study templates or internal SOPs based on the 2002 food-effect bioavailability/fed bioequivalence guidance.

Practical watchpoints

Sponsors should review whether planned or in-progress food-effect studies for oral products are being justified using the older 2002 guidance language that FDA has now partly replaced. Internal references, study-design rationales, and submission narratives may need to point to the May 2026 guidance where it applies. Teams should also distinguish the scope of the new document carefully: FDA describes it as applying to food-effect studies for orally administered drug products conducted under INDs to support NDAs and supplements. The update should therefore be mapped to the specific application pathway and study purpose before changing development plans.

What to monitor next

The immediate next step is operational: sponsors should compare current food-effect study plans and regulatory writing templates against the May 2026 guidance and identify where the older 2002 guidance is still embedded. More broadly, the update is a reminder that FDA is refining clinical pharmacology expectations through targeted guidance revisions rather than replacing entire legacy frameworks at once. Development organizations should track which parts of older bioavailability and bioequivalence guidance remain applicable and which have been superseded.

Sources

• FDA — Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations, May 2026